The health burden of Campylobacter infection and the impact of antimicrobial resistance: Playing chicken

Clinical Infectious Diseases

Volumn 44, Issue 5, 2007, Pages 701-703

  Ruiz Palacios, Guillermo M ^a,b  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b National Medical Science and Nutrition Institute   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC RESISTANCE; CAMPYLOBACTER; COST OF ILLNESS; DIARRHEA; GASTROENTERITIS; GRAM NEGATIVE INFECTION; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; NOTE; PRIORITY JOURNAL;

ANTI-INFECTIVE AGENTS; CAMPYLOBACTER; CAMPYLOBACTER INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; PUBLIC HEALTH PRACTICE;

EID: 33847082547     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/509936     Document Type: Note

References (22)

1. Allos BM. Campylobacter jejuni infections: update on emerging issues and trends. Clin Infect Dis 2001;32:1201-6.
2. Samuel MC, Vugia DJ, Shallow S, et al. Epidemiology of sporadic Campylobacter infection in the United States and declining trend in incidence, FoodNet 1966-1999. Clin Inf Dis 2004;38(Suppl 3):S165-74.
3. Centers for Disease Control and Prevention. Preliminary FoodNet data on the incidence of infection with pathogens transmited commonly through food-10 states, United States, 2005. MMWR Morb Mortal Wkly Rep 2006; 55:392-5.
4. Koehler KM, Lasky T, Fein SB, et al. Population-based incidence of infection with selected bacterial enteric pathogens in children younger than five years of age, 1996-1998. Pediatr Infect Dis J 2006; 25:129-34.
5. Helms M, Simonsen J, Molbak K. Foodborne bacterial infection and hospitalization: a registry-base study. Clin Infect Dis 2006; 42:498-506.
6. Wheeler JG, Sethi D, Cowden JM, et al. Study of infectious intestinal disease in England: rates in the community, presenting to general practice and report to national surveillance. BMJ 1999; 318:1046-50.
7. de Wit MAS, Koopmans MPG, Kortbeek LM, et al. Etiology of gastroenteritis in sentinel general practices in The Netherlands. Clin Infect Dis 2001; 33:280-8.
8. Van Den Brandhof WE, De Wit GA, Van Duynhoven YT. Cost of gastroenteritis in The Netherlands. Epidemiol Infect 2004; 132:211-21.
9. Roberts JA, Cumberland P, Sockett PN, et al. The study of infectious intestinal disease in England: socioeconomic impact. Epidemiol Infect 2003; 130:1-11.
10. Ternhag A, Turner A, Svensson A, et al. Mortality following Campylobacter infection: a registry-based linkage study. BMC Infect Dis 2005; 5:70.
11. Coker AO, Isokpehi RD, Thomas BN, Amisu KO, Obi CL. Human campylobacteriosis in developing countries. Emerg Infect Dis 2002; 8:237-44.
12. Calva JJ, Ruiz-Palacios GM, López-Vidal AB, et al. Cohort study of intestinal infection with Campylobacter in Mexican children. Lancet 1988; 1:503-6.
13. Rao MR, Naficy AB, Savarino SJ, et al. Pathogenicity and convalescent excretion of Campylobacter in rural Egyptian children. Am J Epidemiol 2001; 154:166-73.
14. Albert MJ, Farouque ASG, Farouque SM, et al. Case-control study of enteropathogens associated with childhood diarrhea in Dhaka, Bangladesh. J Clin Microbiol 1999; 37:3458-64.
15. Gupta A, Nelson JM, Barrett TJ, et al. Antimicrobial resistance among Campylobacter strains, United states, 1997-2001. Emerg Infect Dis 2004; 10:1102-9.
16. Smith KE, Besser JM, Hedberg CW, et al. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998. N Engl J Med 1999; 340:1525-32.
17. Reina J, Ros MJ, Serra A. Susceptibilities to 10 antimicrobial agents of 1220 Campylobacter strains isolated from 1987 to 1993 from feces of pediatric patients. Antimicrob Agents Chemother 1994; 38:2917-20.
18. Salazar-Lindo E, Sack B, Chea-Woo E, et al. Early treatment with erythromycin of Campylobacter jejuni associated dysentery in children. J Pediatr 1986; 109:355-60.
19. Taylor DN, Blaser MJ, Echeverria P, et al. Erythromycin-resistant Campylobacter infections in Thailand. Antimicrob Agents Chemother 1987; 31:438-42.
20. Helms M, Simonse J, Olsen KE, et al. Adverse health events associated with antimicrobial drug resistance in Campylobacter species: a registry-based cohort study. J Infect Dis 2005; 191:1050-5.
21. Ternhag A, Asikainen T, Giesecke J, Ekdhal K. A meta-analysis on the effect of antibiotic treatment on duration of symptoms caused by infection with Campylobacter species. Clin Infect Dis 2007;44:696-700 (in this issue).
22. Ruiz-Palacios GM, Cervantes LE, Ramos P, et al. Campylobacter jejuni binds intestinal H(O) antigen (Fuc alpha 1, 2Gal beta 1, 4GlcNAc), and fucosyloligosaccharides of human milk inhibit its binding and infection. J Biol Chem 2003; 278:14112-20.